Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTY
2651
Getty Realty Corp
GTY
$2.04B
| $2.82M | ﹤0.01% |
102,988
+10,594
| +11% | +$293K |
|
2652
Digi International
DGII
$3.23B
| $2.81M | ﹤0.01% |
65,011
+5,074
| +8% | +$203K |
|
2653
Parsons
PSN
$5.16B
| $2.81M | ﹤0.01% |
45,463
-10,635
| -19% | -$832K |
|
|
TWO
2654
Two Harbors Investment
TWO
$1.27B
| $2.81M | ﹤0.01% |
267,420
-71,224
| -21% | -$712K |
|
2655
Castle Biosciences
CSTL
$960M
| $2.81M | ﹤0.01% |
72,149
-919
| -1% | -$29.6K |
|
2656
Astronics
ATRO
$4.57B
| $2.81M | ﹤0.01% |
62,065
+10,364
| +20% | +$435K |
|
2657
Old Second Bancorp
OSBC
$1.31B
| $2.79M | ﹤0.01% |
143,188
+26,609
| +23% | +$497K |
|
2658
Cullinan Oncology
CGEM
$1.26B
| $2.79M | ﹤0.01% |
269,655
+18,545
| +7% | +$167K |
|
|
SOLS
2659
CALL
Solstice Advanced Materials
SOLS
$9.94B
| $2.79M | ﹤0.01% |
+57,450
| New | +$2.7M |
|
2660
Rogers Corp
ROG
$2.48B
| $2.79M | ﹤0.01% |
30,477
+3,972
| +15% | +$341K |
|
2661
Navitas Semiconductor
NVTS
$3.57B
| $2.78M | ﹤0.01% |
388,850
+200,202
| +106% | +$1.93M |
|
2662
Fortuna Silver Mines
FSM
$3.1B
| $2.77M | ﹤0.01% |
282,605
+7,745
| +3% | +$69.7K |
|
2663
Chemours
CC
$2.29B
| $2.77M | ﹤0.01% |
234,956
-701,328
| -75% | -$9M |
|
2664
nLIGHT
LASR
$2.9B
| $2.77M | ﹤0.01% |
73,759
+6,015
| +9% | +$201K |
|
|
HTB
2665
HomeTrust Bancshares
HTB
$831M
| $2.77M | ﹤0.01% |
64,430
-645
| -1% | -$26.6K |
|
2666
Amalgamated Financial
AMAL
$1.53B
| $2.76M | ﹤0.01% |
86,316
+22,444
| +35% | +$653K |
|
2667
Northrim BanCorp
NRIM
$599M
| $2.76M | ﹤0.01% |
103,895
+5,481
| +6% | +$130K |
|
2668
Silgan Holdings
SLGN
$4.3B
| $2.76M | ﹤0.01% |
68,468
-31,883
| -32% | -$1.29M |
|
2669
Harrow
HROW
$1.48B
| $2.76M | ﹤0.01% |
56,380
+2,009
| +4% | +$84.3K |
|
2670
PUT
Remitly
RELY
$5.39B
| $2.76M | ﹤0.01% |
200,000
| – | – |
|
2671
Arlo Technologies
ARLO
$1.5B
| $2.76M | ﹤0.01% |
197,262
+23,897
| +14% | +$376K |
|
2672
Sunstone Hotel Investors
SHO
$2.01B
| $2.76M | ﹤0.01% |
308,643
+2,011
| +0.7% | +$18.4K |
|
2673
PUT
Insulet
PODD
$10.1B
| $2.76M | ﹤0.01% |
9,700
| – | – |
|
2674
Vishay Intertechnology
VSH
$5.11B
| $2.75M | ﹤0.01% |
190,109
-11,363
| -6% | -$172K |
|
2675
Ceco Environmental
CECO
$4.44B
| $2.75M | ﹤0.01% |
45,985
-4,185
| -8% | -$224K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.